Drug Profile
LY 3114062
Alternative Names: LY-3114062Latest Information Update: 28 Jul 2020
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-inflammatories; Antibodies; Antirheumatics; Bispecific antibodies
- Mechanism of Action Interleukin 17 modulators; Tumour necrosis factor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Arthritis
Most Recent Events
- 28 Jul 2020 No recent reports of development identified for phase-I development in Arthritis in Bulgaria (IV, Injection)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Arthritis in Bulgaria (SC, Injection)
- 28 Jul 2020 No recent reports of development identified for phase-I development in Arthritis in Georgia (IV, Injection)